Terms: = Sarcomas AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
345 results:
1. Identification of Germline
Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
[TBL] [Abstract] [Full Text] [Related]
2. The anoikis-related gene signature predicts survival and correlates with immune infiltration in osteosarcoma.
Li J; Wang H; Wu F; Yao J; Zhu H; Zhang M
Aging (Albany NY); 2024 Jan; 16(1):665-684. PubMed ID: 38217543
[TBL] [Abstract] [Full Text] [Related]
3. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (k-ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of epinephrine biosynthesis in hras-mutant paragangliomas.
Li M; Richter S; Mohr H; Drukewitz S; Poser I; Stanke D; Calsina B; Martinez-Montes AM; Quinkler M; Timmers HJLM; Nölting S; Beuschlein F; Remde H; Opocher G; Rapizzi E; Pacak K; Pamporaki C; Robledo M; Liu L; Jiang J; Bornstein SR; Eisenhofer G; Fliedner SMJ; Bechmann N
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902037
[TBL] [Abstract] [Full Text] [Related]
6. Oncologic relevance of genetic alterations in sporadic synchronous and solitary colorectal cancer: a retrospective multicenter study.
Son IT; Kim M; Oh BY; Kim MJ; Yoon SN; Park JH; Kim BC; Kim JW
BMC Gastroenterol; 2023 Sep; 23(1):297. PubMed ID: 37667167
[TBL] [Abstract] [Full Text] [Related]
7. Mutant hras Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract] [Full Text] [Related]
8. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
9. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
[TBL] [Abstract] [Full Text] [Related]
10. Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.
Zhao D; Liu Y; Yi F; Zhao X; Lu K
Eur J Med Chem; 2023 Nov; 259():115698. PubMed ID: 37542991
[TBL] [Abstract] [Full Text] [Related]
11. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
12. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing k-rasG12V and deficient in p53.
Saito H; Suzuki N
Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
[TBL] [Abstract] [Full Text] [Related]
13. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
[TBL] [Abstract] [Full Text] [Related]
14. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract] [Full Text] [Related]
16. Cancer in Costello syndrome: a systematic review and meta-analysis.
Astiazaran-Symonds E; Ney GM; Higgs C; Oba L; Srivastava R; Livinski AA; Rosenberg PS; Stewart DR
Br J Cancer; 2023 Jun; 128(11):2089-2096. PubMed ID: 36966234
[TBL] [Abstract] [Full Text] [Related]
17. Oncogenes and Methionine Addiction of Cancer: Role of
Aoki Y; Han Q; Kubota Y; Masaki N; Obara K; Tome Y; Bouvet M; Nishida K; Hoffman RM
Cancer Genomics Proteomics; 2023; 20(2):165-170. PubMed ID: 36870694
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive analysis of cell death genes in hepatocellular carcinoma based on multi-omics data.
Zhang L; Chen X; Guo X; Shen H; Qiu D; Jin W; Hou D
Adv Clin Exp Med; 2023 Feb; 32(2):233-244. PubMed ID: 36753369
[TBL] [Abstract] [Full Text] [Related]
19. Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm.
Dutta S; Tarafdar S; Mukhopadhyay P; Bhattacharyya NP; Ghosh S
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36744987
[TBL] [Abstract] [Full Text] [Related]
20. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
[Next]
